Revisit new steering committee members in September (loop Connie into this discussion)
Toby to invite Greg from CCDI to the next Executive Team Meeting in January
Toby to look across the NCI directory to find person that has a combination of canine and pediatric oncology background
Agenda
Item
Who
Talking Points
New Steering Committee Members
Toby
New CCDI member to potentially present to Steering Committee, need topics of interest
How can we compare pediatric/human data to canine data
How can our researchers connect to where related human data are accessible
Post Discussion about FidoCure
All
Not clear if we really can have a successful collaboration, however we have let them know if they can find a way to work with us that the ICDC would be interested.
Their public data is a candidate for the ICDC
They are interested in correlating data with biomarkers and that is an area of interest for the ICDC
Work instead with peer reviewed and published scientists that use FidoCure data
Their data may not be useful to predict outcomes
New ICDC Working Group: Longitudinal Data Acquisition and Use Working Group (LDAUWG)
Purpose: Formulate scientific questions and use cases that can be used to interrogate longitudinal datasets that would justify the ingestion of such data into the ICDC.
"Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma"
Dr. Amy LeBlanc
Status: The study, case and sample records were loaded in early September. Sequencing files and file transfer manifest have been transferred to bucket pending validation.
UBC03
"Transcriptomic analyses of early-stage bladder cancer in Scottish Terriers detected through screening"
Dr. Debbie Knapp
Status: Multiple versions of metadata have been received and the final version is in review. Waiting on the File Transfer Manifest.
OSA02
"Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma"
Dr. Dawn Duval
Status: Version 1 of metadata loading files have been received and reviewed. Version 2 is expected soon to address validation errors.
PRECINCT01
"Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases"
UC Davis
21 cases
Status: 21 pathology reports and 5 study-level files, including Nanostring-based evaluation of cytokine levels, have been received and indexed by DCF. Adverse event data has been ingested. Application-level testing revealed several software bugs related to download of the clinical data and fixes are pending by the ICDC team.
PRECINCT02
"Novel treatments for Diffuse large B cell lymphoma (DLBCL) in dogs"
Tufts University
49 cases
Status: Adverse event data has been received and ingested. Visit, vital signs and physical exam data was received and revealed validation errors. Version 2 of these loading files has been received. Lab exam and extent of disease data to be received.
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Action items
John to get disease areas from Sam V.
Toby to reach out to Adam Resnick to gauge interest in joining the Subcommittee